New Research Poster Presentation 3.50: Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder

Thursday, October 29, 2009 12:30 PM

Adelaide Robb, M.D., Children's National Medical Center, Washington, DC

Carlos Fernandez, PharmD, Bristol-Myers Squibb Company, Plainsboro, NJ

Raymond Mankoski, M.D., Ph.D., Bristol-Myers Squibb Company, Plainsboro, NJ

George Manos, Ph.D., Bristol-Myers Squibb Company, Wallingford, CT

Suja Mathew, B.S., Otsuka America Pharmaceutical, Inc., Rockville, MD

Andrei Pikalov, M.D., Ph.D., Otsuka America Pharmaceutical, Inc., Rockville, MD

Randall Owen, M.D., Bristol-Myers Squibb Comopany, Wallingford, CT

Ronald Marcus, M.D., Bristol-Myers Squibb Company, Wallingford, CT

		56th Annual Meeting Tentative Program Schedule
		Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 3.50 Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder